Aytu BioScience (AYTU) AI Stock Analysis

• Market Cap: $25.22M
• Dividend Yield: N/A
• Average Volume (3M): 314.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.82
• Revenue Growth: -15.61%
• EPS Growth: -68.96%
• Country: US
• Employees: 102
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -1.05
• Shares Outstanding: 10,733,208
• 10 Day Avg. Volume: 289,104
• 30 Day Avg. Volume: 314,725
• PEG Ratio: 0.04
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 0.21
• P/FCF Ratio: -2.65
• Enterprise Value/Market Cap: 0.46
• Enterprise Value/Revenue: 0.19
• Enterprise Value/Gross Profit: 0.28
• Enterprise Value/Ebitda: -0.68
• 1Y Price Target: $9.33
• Price Target Upside: 305.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $2.50 ▲(8.70% Upside)

The score is held down primarily by weak financial performance (revenue contraction, continuing losses, negative free cash flow, and rising leverage). Technicals add a near-term bearish tilt (below 20/50-day averages with weak momentum). Offsetting factors are a moderately constructive earnings-call outlook driven by early EXXUA launch traction and spend discipline, while valuation remains constrained due to negative earnings and no dividend.

Positive Factors

First-in-class EXXUA launch

EXXUA’s differentiated 5-HT1A mechanism creates a durable commercial opportunity in MDD by addressing unmet needs (non-responders and side-effect intolerant patients). A unique, approved therapy supports longer-term market access, clinician adoption, and portfolio diversification versus legacy ADHD/pediatric reliance.

Patient access & distribution strength

Aytu’s RxConnect program materially improves patient affordability, distribution control and payer engagement, reducing friction for branded uptake. Durable access infrastructure supports sustained prescription flow, better adherence economics, and improved launch scalability across channels and payers over months to years.

Resilient ADHD revenue base

Aytu retains a sizable, relatively stable ADHD revenue stream that provides recurring cash inflow while EXXUA scales. This legacy franchise cushions near-term variability, funds commercialization, and offers a fallback revenue runway even as management rebalances promotional focus to new product launches.

Negative Factors

Revenue contraction & negative cash flow

Persistent revenue decline and negative operating/free cash flow reduce internal funding capacity and heighten dependence on external capital. Over 2–6 months this constrains sustained launch investment, increases dilution risk, and limits the company’s ability to absorb slower-than-expected EXXUA uptake or payer delays.

Eroding equity & higher leverage

Rising leverage and diminished shareholder equity weaken financial flexibility and increase refinancing and covenant risk. In a specialty pharma model that needs upfront commercial spend, a strained balance sheet amplifies vulnerability to reimbursement setbacks and limits optionality for acquisitions or supplemental funding.

Operating losses and negative adjusted EBITDA

Operating costs continue to outstrip gross profit despite solid unit margins, keeping the business structurally unprofitable. Sustained negative EBITDA means sizable net-revenue gains are required to reach breakeven, increasing execution risk if EXXUA uptake or ADHD stabilization underperform expectations.

Aytu BioScience Business Overview & Revenue Model

Company Description

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

How the Company Makes Money

Aytu BioScience generates revenue through the sale of its pharmaceutical products and diagnostic tests. The company has a diversified revenue model that includes direct sales of its proprietary products, as well as partnerships with other pharmaceutical companies for co-promotion and distribution. Key revenue streams are derived from product sales in the urology and pediatric markets, where Aytu has established a presence. Additionally, the company may benefit from licensing agreements, collaborations, and research grants that contribute to its financial performance. Strategic partnerships with healthcare providers and institutions also play a crucial role in expanding its market reach and enhancing sales.

Aytu BioScience Financial Statement Overview

Summary

Financial statements indicate a pressured profile: sharply weaker TTM revenue, ongoing operating and net losses, and negative operating/free cash flow. Balance-sheet risk is elevated as equity has eroded and leverage has risen, increasing dependence on improved execution and/or external funding despite relatively strong gross margins.

Income Statement

AYTU’s revenue trend has weakened materially, with TTM (Trailing-Twelve-Months) revenue down sharply versus the prior annual periods. While gross margin remains relatively strong in TTM (about two-thirds of revenue) and improved versus the 2021–2023 range, the business is still structurally unprofitable: TTM operating results and net income are meaningfully negative, and profitability has deteriorated versus FY2025 (annual) where losses were smaller. The key strength is the ability to generate solid gross profit on sales; the key weakness is that operating costs and other expenses continue to overwhelm that gross profit, keeping margins deeply negative.

Balance Sheet

Leverage has increased and the equity base has eroded. Total debt is roughly flat recently, but stockholders’ equity declined notably from FY2025 (annual) to TTM (Trailing-Twelve-Months), which pushed debt-to-equity higher (now well above 1x). Return on equity remains significantly negative, reflecting ongoing losses and pressure on shareholder capital. A positive is that the company still reports a meaningful asset base; the primary risk is rising balance-sheet strain as losses reduce equity, making the capital structure less resilient.

Cash Flow

Cash generation remains a concern. TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both negative, and free cash flow fell meaningfully versus the most recent annual period, even if the absolute cash burn is smaller than the very large outflows seen in earlier years. One relative positive is that cash burn has moderated substantially from FY2021–FY2022 levels; however, the business is still not self-funding, and persistent negative free cash flow increases dependence on external capital or balance-sheet flexibility.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	66.38M	65.18M	107.40M	96.67M	65.63M
Gross Profit	45.83M	49.05M	66.63M	50.28M	29.20M
EBITDA	-4.67M	1.41M	-3.27M	-27.96M	-29.04M
Net Income	-13.56M	-15.84M	-17.05M	-108.78M	-58.29M
Balance Sheet
Total Assets	124.18M	118.86M	137.84M	137.62M	265.67M
Cash, Cash Equivalents and Short-Term Investments	30.95M	20.01M	22.98M	19.36M	49.65M
Total Debt	22.94M	16.42M	30.43M	18.19M	30.97M
Total Liabilities	105.21M	91.14M	98.48M	93.31M	128.10M
Stockholders Equity	18.97M	27.72M	39.36M	44.31M	137.57M
Cash Flow
Free Cash Flow	-5.17M	-1.72M	-5.13M	-28.82M	-25.96M
Operating Cash Flow	-1.94M	-1.39M	-5.13M	-28.82M	-25.96M
Investing Cash Flow	-2.56M	-329.00K	-117.00K	-3.25M	-2.78M
Financing Cash Flow	15.44M	-1.26M	8.87M	1.53M	30.31M

Aytu BioScience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AYTU, the sentiment is Negative. The current price of 2.3 is below the 20-day moving average (MA) of 2.63, below the 50-day MA of 2.49, and above the 200-day MA of 2.18, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 36.82 is Neutral, neither overbought nor oversold. The STOCH value of 32.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AYTU.

Aytu BioScience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TXMD	52 Neutral	$26.04M	83.91	0.27%	―	75.19%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FLGC	50 Neutral	$27.69M	-0.24	-37.38%	―	-22.60%	53.82%
AYTU	45 Neutral	$25.22M	-0.60	-50.23%	―	-15.61%	-68.96%
COSM	40 Underperform	$17.52M	-0.62	-63.82%	―	―	―

Aytu BioScience Corporate Events

Aytu BioPharma Highlights EXXUA Opportunity at Investor Day

On January 20, 2026, Aytu BioPharma held an Investor Day in New York City, with in-person and webcast participation, to spotlight the commercial and clinical opportunity for EXXUA (gepirone) extended-release tablets, which had been launched the prior month as the first FDA-approved 5HT1a agonist for major depressive disorder. Key opinion leaders in psychiatry and company executives reviewed EXXUA’s differentiated mechanism of action compared with traditional SSRIs and SNRIs, underscoring its targeted 5HT1a activity and lack of activity at receptors associated with sexual dysfunction and weight gain, and they presented Phase 3 data showing statistically significant improvements in depression scores versus placebo, early onset of remission benefits, and a generally favorable safety and tolerability profile. The event framed EXXUA as a potential alternative for the large share of MDD patients who either fail first-line therapies or discontinue due to side effects, signaling Aytu’s bid to strengthen its position in the CNS depression market and highlighting a potentially important new treatment option for clinicians and patients confronting high rates of non-remission, functional impairment, and treatment-related sexual and weight side effects.

The most recent analyst rating on (AYTU) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Aytu BioScience Stockholders Approve Key Proposals

On December 10, 2025, Aytu BioPharma, Inc. held its 2026 annual meeting of stockholders. During this meeting, stockholders voted on three key proposals. All incumbent directors standing for reelection were successfully elected by a majority vote. Additionally, the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026, was ratified. Lastly, the stockholders approved the executive compensation proposal through a non-binding advisory vote.

The most recent analyst rating on (AYTU) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.